Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCX-001 Cream in Healthy Volunteers With Induced Dermal Incisions
NCT03036306Phase 1Completed
- Sponsor
- ScarX Therapeutics
- Start
- Jan 2017
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nefopam in scarring, sponsored by ScarX Therapeutics. Primary endpoint: Adverse Events at 4 months. Started Jan 2017; status: completed.
02
Drugs
nefopam
03
Conditions
scarring
Beyond the preview
Go deeper on NCT03036306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03036306.